Malaria remains a major global health burden. The pathogen, Plasmodium falciparum, has evolved strategies to evade the host immune system, complicating efforts to develop effective vaccines and therapies. Among the host's first lines of defense, macrophages play an indispensable role in recognizing and eliminating pathogens, including malaria parasites. These phagocytic cells patrol the bloodstream and tissues, scavenging infected or abnormal cells through the detection of surface molecular signals. However, the precise molecular mechanisms by which Plasmodium specifically modulates infected red blood cells to escape macrophage surveillance have remained elusive for decades.
To address this gap, the research team used both the human-infective P. falciparum 3D7 strain and the mouse-infective P. berghei ANKA model, allowing for comparative and translational insights. Published on April 14, 2026, in Volume 2, article number 20 of the journal Immunity & Inflammation , a key finding emerged: Plasmodium PI3K actively suppresses the externalization of phosphatidylserine—a classic "eat-me" signal—on the surface of infected erythrocytes. When the activity of parasite PI3K was chemically inhibited or genetically disrupted, phosphatidylserine exposure on infected red blood cells increased markedly.
Phosphatidylserine externalization serves as a potent pro-phagocytic signal. The study demonstrated that increased exposure of this lipid drives host monocytes to polarize toward M2-type macrophages and significantly enhances the recognition, adhesion, and phagocytosis of infected erythrocytes by these macrophages. Blocking parasite PI3K activity leads to increased macrophage-mediated clearance of infected cells, reduced parasite burden, and improved survival outcomes. "These results provide compelling evidence that Plasmodium uses its intrinsic PI3K to maintain a state of immune invisibility within the host," the authors pointed out.
At the molecular level, the study dissected two interconnected pathways through which parasite PI3K maintains phosphatidylserine internalization. First, Plasmodium PI3K directly phosphorylates and inhibits the activity of Plasmodium phospholipid scramblase 1 (PfPLSCR1), the enzyme responsible for flipping phosphatidylserine from the inner to the outer leaflet of the cell membrane. By blocking this scramblase, the parasite prevents the externalization signal at its source.
Second, parasite PI3K promotes 2-hydroxyisobutyrylation of the parasite's mitochondrial 14-3-3 protein, a post-translational modification that helps maintain mitochondrial membrane potential stability and prevents aberrant calcium release from intracellular stores. As the activity of PfPLSCR1 is highly dependent on elevated cytoplasmic calcium concentrations, the PI3K-mediated maintenance of calcium homeostasis further suppresses scramblase activation. "This dual mechanism ensures that phosphatidylserine remains sequestered on the inner leaflet, allowing the parasite to evade immune detection," the authors concluded.
This work systematically elucidates how Plasmodium exploits a specific kinase network to manipulate host cell membrane lipid asymmetry. The discovery not only deepens scientific understanding of host–pathogen interactions and immune evasion strategies in falciparum malaria but also identifies a valuable new antimalarial target. "By pharmacologically inhibiting parasite PI3K activity—using existing or newly developed small molecule inhibitors—it may be possible to promote host macrophage recognition and clearance of infected red blood cells," the authors proposed, "This strategy would be fundamentally different from current antimalarials that directly kill the parasite, instead harnessing the host's own immune system to achieve parasite elimination." Thus, targeting Plasmodium PI3K offers a novel therapeutic approach for malaria intervention.
